Cyxone ABFRA Cyxone Stock Report

Cyxone AB is a clinical stage biotechnology company, which engages in the development of immunomodulation drugs for the treatment of autoimmune diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2016-06-07. The firm develops cyclotide drugs for autoimmune and other diseases. The firm's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The firm's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The firm has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.